MedPath

Victoza

These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010

Approved
Approval ID

35e613e3-7aae-4152-b827-99d1ee7841be

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 6, 2023

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

liraglutide

PRODUCT DETAILS

NDC Product Code50090-4503
Application NumberNDA022341
Marketing CategoryC73594
Route of AdministrationSUBCUTANEOUS
Effective DateJune 10, 2022
Generic Nameliraglutide

INGREDIENTS (7)

LIRAGLUTIDEActive
Quantity: 6 mg in 1 mL
Code: 839I73S42A
Classification: ACTIB
PHENOLInactive
Quantity: 5.5 mg in 1 mL
Code: 339NCG44TV
Classification: IACT
PROPYLENE GLYCOLInactive
Quantity: 14 mg in 1 mL
Code: 6DC9Q167V3
Classification: IACT
SODIUM PHOSPHATE, DIBASIC, DIHYDRATEInactive
Quantity: 1.42 mg in 1 mL
Code: 94255I6E2T
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: CNTM
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: CNTM
© Copyright 2025. All Rights Reserved by MedPath
Victoza - FDA Approval | MedPath